- Home
- CYTO vs PHIO Comparison
CYTO vs PHIO Comparison
Compare CYTO & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTO
- PHIO
- Stock Information
- Founded
- CYTO 2003
- PHIO 2011
- Country
- CYTO Bermuda
- PHIO United States
- Employees
- CYTO N/A
- PHIO N/A
- Industry
- CYTO Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CYTO Health Care
- PHIO Health Care
- Exchange
- CYTO Nasdaq
- PHIO Nasdaq
- Market Cap
- CYTO 2.2M
- PHIO 2.3M
- IPO Year
- CYTO N/A
- PHIO N/A
- Fundamental
- Price
- CYTO $0.46
- PHIO $2.21
- Analyst Decision
- CYTO
- PHIO Strong Buy
- Analyst Count
- CYTO 0
- PHIO 1
- Target Price
- CYTO N/A
- PHIO $36.00
- AVG Volume (30 Days)
- CYTO 106.0K
- PHIO 41.4K
- Earning Date
- CYTO 09-24-2024
- PHIO 11-14-2024
- Dividend Yield
- CYTO N/A
- PHIO N/A
- EPS Growth
- CYTO N/A
- PHIO N/A
- EPS
- CYTO N/A
- PHIO N/A
- Revenue
- CYTO N/A
- PHIO N/A
- Revenue This Year
- CYTO N/A
- PHIO N/A
- Revenue Next Year
- CYTO N/A
- PHIO N/A
- P/E Ratio
- CYTO N/A
- PHIO N/A
- Revenue Growth
- CYTO N/A
- PHIO N/A
- 52 Week Low
- CYTO $0.40
- PHIO $2.17
- 52 Week High
- CYTO $17.20
- PHIO $18.81
- Technical
- Relative Strength Index (RSI)
- CYTO 35.16
- PHIO 32.01
- Support Level
- CYTO $0.40
- PHIO $2.49
- Resistance Level
- CYTO $0.62
- PHIO $3.70
- Average True Range (ATR)
- CYTO 0.06
- PHIO 0.31
- MACD
- CYTO 0.00
- PHIO -0.10
- Stochastic Oscillator
- CYTO 25.18
- PHIO 2.75
About CYTO Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.